A new treatment approach for ovarian cancer using a SIK2 inhibitor to improve therapy effectiveness.
The SIK2 Inhibitor GRN-300 Enhances PARP Inhibitor Sensitivity and Cytotoxic T-Cell Function in Ovarian Cancer
This study is testing a new drug called GRN-300 to see if it can make existing ovarian cancer treatments work better, especially when used with other medications like paclitaxel and olaparib, to help patients have better results.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-10931355 on NIH RePORTER |
What this research studies
This research investigates the use of a novel SIK2 inhibitor, GRN-300, to enhance the effectiveness of existing ovarian cancer treatments, specifically carboplatin and paclitaxel. The approach includes a first-in-human trial to determine the maximum tolerated dose of GRN-300 alone and in combination with weekly paclitaxel. Additionally, preclinical studies have shown that GRN-300 can increase sensitivity to olaparib, a drug used in treating certain types of ovarian cancer. By targeting specific pathways involved in DNA repair, this research aims to overcome resistance to current therapies and improve patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are women diagnosed with ovarian cancer, particularly those who have experienced resistance to standard treatments.
Not a fit: Patients with non-ovarian cancers or those who have not been diagnosed with ovarian cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for women with ovarian cancer, potentially improving survival rates and quality of life.
How similar studies have performed: Previous research has shown promising results with similar approaches, indicating potential for significant advancements in ovarian cancer treatment.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Bast, Robert C — University of Tx Md Anderson Can Ctr
- Study coordinator: Bast, Robert C
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.